Key result
PARP1 deficiency triggers age-dependent cardiac hypertrophy and dysfunction via Akt hyperactivation in mice.
Why the study?
While PARP1 inhibition protects cardiomyocytes against oxidative stress and ischemia-reperfusion injury, the role of PARP1 in aging-associated heart failure remained unexplored.
Does PARP1 deficiency induce aging-associated cardiac remodeling and heart failure via activation of Akt signaling, and can Akt inhibition rescue this cardiac dysfunction in preclinical models?
Does PARP1 deficiency induce aging-associated cardiac remodeling and heart failure via activation of Akt signaling, and can Akt inhibition rescue this cardiac dysfunction in preclinical models?
This preclinical study demonstrates that age-related loss of PARP1 drives pathological cardiac hypertrophy and heart failure via chronic Akt hyperactivation, suggesting that chronic PARP1 inhibition in elderly patients could adversely affect cardiac function.
Answers are grounded in this paper and cite their sources.
PARP1 inhibition merits exploration in aging HF; extends prior IR protection data but leaves open clinical translation.
PARP1, a major poly-ADP-ribose transferase, plays a critical role in maintaining genomic stability, transcription, cellular energy metabolism, and cell death. In the heart, PARP1 inhibition protects cardiomyocytes against oxidative and genotoxic stress and attenuates ischemia-reperfusion injury caused by myocardial infarction. However, the role of PARP1 in aging-associated heart failure remains unexplored. In this study, we demonstrate the crucial role of PARP1 in regulating aging-associated cardiac remodelling and failure. The levels of PARP1 are down-regulated in aging mouse hearts, and PARP1 deficiency induces aging-related cardiac remodelling and contractile dysfunction in mice. The RNA-seq analysis revealed hyperactivation of Akt signalling, a major signalling pathway involved in aging, in PARP1-deficient hearts. In the heart, PARP1 deficiency spontaneously activates the Akt signalling pathway, leading to the development of aging-related cardiac hypertrophy and failure. Our findings reveal two distinct mechanisms by which PARP1 regulates Akt signalling, involving the direct interaction of PARP1 with Akt and the transcriptional regulation of phosphatases, including the expression of PTEN by PARP1. Mechanistically, PARP1 binds to the PTEN promoter and might transcriptionally promote its expression. In addition, PARP1 binds and inhibits Akt by poly-ADP-ribosylating Akt at the PH domain, which impairs Akt plasma membrane recruitment and subsequent activation. Inhibition of Akt reversed hypertrophy in PARP1-depleted cardiomyocytes and improved the contractile dysfunction in PARP1-deficient hearts. These findings reveal a previously unrecognized regulatory role for PARP1 in aging-associated cardiac failure.
No takes yet. Share an insight, caveat, or question.
Sundaresan et al. (2026) studied Aging-associated cardiac remodelling and heart failure. PARP1 deficiency (knockout/knockdown/benzamide) and Akt inhibition (AKTi-1/2) vs. Wild-type mice, scrambled siRNA, or vehicle control was evaluated on Age-dependent cardiac remodeling and contractile dysfunction (ejection fraction, fractional shortening, hypertrophy, and Akt signaling activation). PARP1 deficiency induced spontaneous age-dependent cardiac hypertrophy and contractile dysfunction in mice via hyperactivation of Akt signaling, which was rescued by pharmacological Akt inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: